Company intelligence / Profile preview
Changchun Intellicrown Pharmaceutical Co., Ltd.
Changchun, Jilin, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Changchun Intellicrown Pharmaceutical is conducting early-stage clinical trials for oncology and metabolic disease indications. Its lead assets include a CTLA4 inhibitor and an EGFR antagonist, both in Phase 1 trials for advanced solid tumors, as well as a program in nonalcoholic steatohepatitis also at the Phase 1 stage. No late-stage or approved products are reported as of now[1][5].
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small molecule drugsFusion proteinsMonoclonal antibodies[1]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Changchun Intellicrown Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changchun Intellicrown Pharmaceutical Co., Ltd..